ArticlePloS one2014
Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Glioblastoma invasion patterns from a clinical perspective-a systematic review.Neurosurgical review · 2024Pooled it
- The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.Neuro-oncology · 2018Trial
- Identification of SAMD9 as an adaptive response gene to environmental changes and its association with overall survival and immunotherapeutic response in glioblastoma.Cancer cell international · 2025Article
- Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study.Annals of translational medicine · 2022Article
- Physiological MRI Biomarkers in the Differentiation Between Glioblastomas and Solitary Brain Metastases.Molecular imaging and biology · 2021Article
- The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution.Scientific reports · 2020Article
- Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.PLoS medicine · 2019Observational
- Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.Cancer communications (London, England) · 2019Article
- The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: in 3D in Vitro ModelAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Article
- Blood-brain barrier-on-a-chip: Microphysiological systems that capture the complexity of the blood-central nervous system interface.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.Journal of neuro-oncology · 2017Article
- Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary.PloS one · 2017Article
- Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?Journal of neuro-oncology · 2016Article
- Fast and high temperature hyperthermia coupled with radiotherapy as a possible new treatment for glioblastoma.Journal of therapeutic ultrasound · 2016Article
- Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.PloS one · 2016Article
- In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma.Journal of the Royal Society, Interface · 2015Article
- Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.Frontiers in oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Glioblastoma multiforme (GBM) causes significant neurological morbidity and short survival times. Brain invasion by GBM is associated with poor prognosis. Recent clinical trials of bevacizumab in newly-diagnosed GBM found no beneficial effects on overall survival times; however, the baseline health-related quality of life and performance status were maintained longer in the bevacizumab group and the glucocorticoid requirement was lower. Here, we construct a clinical-scale model of GBM whose predictions uncover a new pattern of recurrence in 11/70 bevacizumab-treated patients. The findings support an exception to the Folkman hypothesis: GBM grows in the absence of angiogenesis by a cycle of proliferation and brain invasion that expands necrosis. Furthermore, necrosis is positively correlated with brain invasion in 26 newly-diagnosed GBM. The unintuitive results explain the unusual clinical effects of bevacizumab and suggest new hypotheses on the dynamic clinical effects of migration by active transport, a mechanism of hypoxia-driven brain invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.